DE69533408D1 - Chinolinderivate als Tachykinin NK3 Rezeptor Antagonisten - Google Patents

Chinolinderivate als Tachykinin NK3 Rezeptor Antagonisten

Info

Publication number
DE69533408D1
DE69533408D1 DE69533408T DE69533408T DE69533408D1 DE 69533408 D1 DE69533408 D1 DE 69533408D1 DE 69533408 T DE69533408 T DE 69533408T DE 69533408 T DE69533408 T DE 69533408T DE 69533408 D1 DE69533408 D1 DE 69533408D1
Authority
DE
Germany
Prior art keywords
tachykinin
receptor antagonists
quinoline derivatives
quinoline
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69533408T
Other languages
English (en)
Other versions
DE69533408T2 (de
Inventor
Carlo Farina
Giuseppe Arnaldo Mari Giardina
Mario Grugni
Luca Francesco Raveglia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline SpA
Original Assignee
GlaxoSmithKline SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT94MI001099A external-priority patent/ITMI941099A1/it
Priority claimed from IT95MI000494 external-priority patent/IT1293558B1/it
Application filed by GlaxoSmithKline SpA filed Critical GlaxoSmithKline SpA
Publication of DE69533408D1 publication Critical patent/DE69533408D1/de
Application granted granted Critical
Publication of DE69533408T2 publication Critical patent/DE69533408T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
DE69533408T 1994-05-27 1995-05-23 Chinolinderivate als Tachykinin NK3 Rezeptor Antagonisten Expired - Lifetime DE69533408T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IT94MI001099A ITMI941099A1 (it) 1994-05-27 1994-05-27 Derivati chinolinici
ITMI941099 1994-05-27
IT95MI000494 IT1293558B1 (it) 1995-03-14 1995-03-14 Derivati chinolinici
ITMI950494 1995-03-14

Publications (2)

Publication Number Publication Date
DE69533408D1 true DE69533408D1 (de) 2004-09-23
DE69533408T2 DE69533408T2 (de) 2005-09-08

Family

ID=26331143

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69533408T Expired - Lifetime DE69533408T2 (de) 1994-05-27 1995-05-23 Chinolinderivate als Tachykinin NK3 Rezeptor Antagonisten
DE69531458T Expired - Lifetime DE69531458T2 (de) 1994-05-27 1995-05-23 Chinolinderivate als tachykinin nk3 rezeptor antagonisten

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69531458T Expired - Lifetime DE69531458T2 (de) 1994-05-27 1995-05-23 Chinolinderivate als tachykinin nk3 rezeptor antagonisten

Country Status (35)

Country Link
US (5) US6608083B1 (de)
EP (2) EP0804419B1 (de)
JP (5) JP3664492B2 (de)
KR (1) KR100316571B1 (de)
CN (3) CN1092642C (de)
AP (1) AP578A (de)
AR (1) AR037069A2 (de)
AT (2) ATE246677T1 (de)
AU (1) AU699319B2 (de)
BG (2) BG64004B1 (de)
BR (1) BR9507788A (de)
CA (1) CA2191352C (de)
CZ (1) CZ291476B6 (de)
DE (2) DE69533408T2 (de)
DK (1) DK0804419T3 (de)
DZ (1) DZ1889A1 (de)
ES (2) ES2227769T3 (de)
FI (2) FI115052B (de)
HK (2) HK1003884A1 (de)
HU (1) HU226535B1 (de)
IL (1) IL113844A (de)
MA (1) MA23560A1 (de)
MX (1) MX9605903A (de)
MY (1) MY129596A (de)
NO (2) NO307783B1 (de)
NZ (1) NZ287442A (de)
OA (1) OA10592A (de)
PL (2) PL186075B1 (de)
PT (2) PT940391E (de)
RO (1) RO114445B1 (de)
SA (1) SA95160290B1 (de)
SK (2) SK282722B6 (de)
TW (2) TW427977B (de)
UA (1) UA51623C2 (de)
WO (1) WO1995032948A1 (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100316571B1 (ko) * 1994-05-27 2002-05-30 파올로 비지, 엔리꼬 카쭐라니 타키키닌nk3수용체길항제로서퀴놀린유도체
GB9524104D0 (en) * 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
GB9524137D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
AU757836B2 (en) * 1995-11-24 2003-03-06 Smithkline Beecham Spa Quinoline derivatives
AP9801237A0 (en) * 1995-11-24 1998-06-30 Smithkline Beecham Farm S P A Quinoline derivatives.
WO1998041506A1 (en) * 1997-03-14 1998-09-24 Smithkline Beecham Corporation Novel quinoline- and naphthalenecarboxamides, pharmaceutical compositions and methods of inhibiting calpain
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US20010012846A1 (en) * 1997-05-23 2001-08-09 Glardina Giuseppe Arnaldo Maria Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists
EP0983262B1 (de) * 1997-05-23 2003-07-09 GlaxoSmithKline S.p.A. Chinolin-4-carboxamidderivate als nk-2 und nk-3 rezeptor antagonisten
EP1652840A3 (de) * 1997-09-17 2006-05-17 Smithkline Beecham Corporation (-)-(S)-N-(.alpha.-Ethylbenzyl)-3-hydroxy-2-phenylchinolin-4-carboxamid
AP1201A (en) * 1997-09-17 2003-09-01 Smithkline Beecham Corp Method for the synthesis of quinoline derivatives.
US6083944A (en) * 1997-10-07 2000-07-04 Cephalon, Inc. Quinoline-containing α-ketoamide cysteine and serine protease inhibitors
GB9825554D0 (en) 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
US6780875B2 (en) * 1998-11-20 2004-08-24 Smithkline Beecham S.P.A. Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
TR200101412T2 (tr) * 1998-11-20 2001-10-22 Smithkline Beecham S.P.A. Yeni bileşikler.
JP2002535274A (ja) * 1999-01-25 2002-10-22 スミスクライン・ビーチャム・コーポレイション 抗アンドロゲン剤および疾病の治療方法
US7037922B1 (en) 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
WO2000058303A1 (en) 1999-03-29 2000-10-05 Neurogen Corporation 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands
WO2000064877A1 (en) 1999-04-26 2000-11-02 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
AU2001276556A1 (en) * 2000-08-11 2002-02-25 Smithkline Beecham P.L.C. Novel pharmaceutical use of quinnoline derivatives
GB0028964D0 (en) * 2000-11-28 2001-01-10 Smithkline Beecham Spa Novel compounds
US6540733B2 (en) * 2000-12-29 2003-04-01 Corazon Technologies, Inc. Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
ATE313539T1 (de) * 2001-04-11 2006-01-15 Glaxosmithkline Spa Chinolin-4-carboxamidderivate als nk-3 und nk-2 rezeptor antagonisten
US20040152727A1 (en) * 2001-05-18 2004-08-05 Hay Douglas William Pierre Novel use
WO2004002484A1 (ja) * 2002-06-26 2004-01-08 Kyowa Hakko Kogyo Co., Ltd. ホスホジエステラーゼ阻害剤
GB0228288D0 (en) * 2002-12-04 2003-01-08 Smithkline Beecham Corp Chemical compounds
GB0228287D0 (en) * 2002-12-04 2003-01-08 Smithkline Beecham Corp Chemical compounds
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
SE0302139D0 (sv) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
US7988964B2 (en) 2003-12-22 2011-08-02 Glaxo Group Limited NOGO-a neutralising immunoglobulin for treatment of neurological diseases
OA13365A (en) 2004-02-04 2007-04-13 Pfizer Prod Inc Substituted quinoline compounds.
EP1729751A1 (de) * 2004-03-25 2006-12-13 Smithkline Beecham Corporation Verwendung eines nk3-antagonisten zur behandlung von bipolaren störungen
BRPI0508111A (pt) * 2004-03-30 2007-07-17 Smithkline Beecham Corp composições farmacêuticas secas por aspersão
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
EP2530075A3 (de) * 2004-06-24 2014-12-24 Vertex Pharmaceuticals Incorporated Modulatoren von Transportern der ATP-bindenden Kassette
GB0417560D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Therapeutic compounds
GB0417559D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Therapeutic compounds
GB0425075D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0425077D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0425076D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0428233D0 (en) * 2004-12-23 2005-01-26 Glaxo Group Ltd Compounds
CA2611060A1 (en) * 2005-06-03 2006-12-07 R. Thomas Simpson Quinoline derivatives as nk3 antagonists
AU2006259890A1 (en) * 2005-06-23 2006-12-28 Astrazeneca Ab Quinoline 3 -sulfonate esters as NK3 receptor modulators
GB0515580D0 (en) 2005-07-29 2005-09-07 Merck Sharp & Dohme Therapeutic compounds
EP1919871A4 (de) * 2005-08-02 2010-08-18 Glaxosmithkline Llc Verfahren zur synthese von chinolinderivaten
US20080280949A1 (en) * 2005-08-11 2008-11-13 Astrazeneca Ab Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators
WO2007018465A1 (en) * 2005-08-11 2007-02-15 Astrazeneca Ab Amide alkyl pyridiyl quinolines as nk3 receptor modulators
AR058051A1 (es) * 2005-09-21 2008-01-23 Astrazeneca Ab Quinolinas de alquilnitrilo.proceso de obtencion y composiciones farmaceuticas.
EP1940795A1 (de) * 2005-09-21 2008-07-09 AstraZeneca AB N-oxo-heterocyclyl- und n-oxo-alkylchinolin-4-carbonsäureamide als liganden des nk-3-rezeptors
AR057130A1 (es) * 2005-09-21 2007-11-14 Astrazeneca Ab Quinolinas de alquilsulfoxido y una composicion farmaceutica
TW201018662A (en) * 2005-12-12 2010-05-16 Astrazeneca Ab Alkylsulphonamide quinolines
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
CA2634113A1 (en) * 2005-12-24 2007-07-05 Vertex Pharmaceuticals Incorporated Quinolin- 4 - one derivatives as modulators of abc transporters
AU2006332726B2 (en) 2005-12-28 2012-12-13 Vertex Pharmaceuticals Incorporated. Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CN101410392A (zh) * 2006-01-27 2009-04-15 阿斯利康(瑞典)有限公司 酰胺取代的喹啉类化合物
GB0603087D0 (en) * 2006-02-15 2006-03-29 Glaxo Group Ltd Novel use
BRPI0809106A2 (pt) 2007-03-22 2014-08-26 Astrazeneca Ab Derivados de quinolina para o tratamento de doenças inflamatórias
US8173639B2 (en) 2007-04-26 2012-05-08 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists
WO2008131779A1 (en) * 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
WO2009026408A1 (en) * 2007-08-22 2009-02-26 Allergan, Inc. Therapeutic quinoline and naphthalene derivatives
WO2009049791A2 (en) * 2007-10-15 2009-04-23 F. Hoffmann-La Roche Ag Radiolabeled nk3 receptor antagonist
PE20091036A1 (es) 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7
MX2010013868A (es) 2008-06-23 2011-02-24 Lundbeck & Co As H Derivados de isoquinolinona como antagonistas de nk3.
US8242134B2 (en) 2008-09-15 2012-08-14 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists
EA201170585A1 (ru) 2008-10-20 2011-12-30 Х. Лундбекк А/С Производные изохинолинона в качестве антагонистов nk3
SG10201504084QA (en) 2009-03-20 2015-06-29 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
TW201143768A (en) 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
TW201144311A (en) 2010-03-12 2011-12-16 Lundbeck & Co As H Azaisoquionolinone derivatives as NK3 antagonists
US8487102B2 (en) * 2010-04-20 2013-07-16 Hoffmann-La Roche Inc. Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US9346814B2 (en) 2012-01-17 2016-05-24 Universiteit Antwerp FAP inhibitors
CN109966264A (zh) 2012-02-27 2019-07-05 沃泰克斯药物股份有限公司 药物组合物及其施用
CN102702099A (zh) * 2012-06-21 2012-10-03 江苏恩华药业股份有限公司 (s)-3-羟基-2-苯基-n-(1-苯基丙基)喹啉-4-甲酰胺的制备方法
WO2014170648A1 (en) 2013-04-19 2014-10-23 Astrazeneca Ab A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
EP3160469B1 (de) 2014-06-25 2021-04-28 Emory University Verfahren zur verwaltung von bedingter angst mit neurokinin-rezeptor-antagonisten
WO2016004035A1 (en) * 2014-07-01 2016-01-07 Icahn School Of Medicine At Mount Sinai 2-aryl-4-quinolinecarboxamide derivatives for treating thyroid diseases
US10189788B2 (en) 2014-09-09 2019-01-29 Bayer Pharma Aktiengesellschaft Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents
WO2016057730A1 (en) 2014-10-07 2016-04-14 Strohmeier Mark Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
JP2018512404A (ja) 2015-03-18 2018-05-17 バイエル ファーマ アクチエンゲゼルシャフト 置換ｎ−ビシクロ−２−アリール−キノリン−４−カルボキサミドおよびその使用
PL3297631T3 (pl) * 2015-05-18 2020-03-31 Nerre Therapeutics Limited Antagoniści receptora NK-1/NK-3 do leczenia uderzeń gorąca
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides
WO2017153231A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-2-arylisochinolinon-4-carboxamide und ihre verwendung
WO2017153235A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung
WO2017153234A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-2-arylchinolin-4-carboxamide und ihre verwendung
CN105884626B (zh) * 2016-05-04 2017-10-20 龙曦宁（上海）医药科技有限公司 一种2‑氨基茚满衍生物的合成方法及其产品
AU2018251758B2 (en) 2017-04-10 2021-11-18 Bayer Aktiengesellschaft Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof
TWI770157B (zh) 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
EP3704271A4 (de) 2017-11-02 2021-09-08 California Institute of Technology Neurokinin-antagonisten und verwendung davon
WO2020101017A1 (ja) * 2018-11-15 2020-05-22 国立大学法人九州大学 Ｉｌ－３１介在性疾患の予防又は治療剤及び医薬組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1560489A (en) * 1976-05-21 1980-02-06 Fisons Ltd Pharmaceutical compositions
FR2538388B1 (fr) 1982-12-24 1985-06-21 Pharmuka Lab Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments
DE3905339A1 (de) * 1989-02-22 1990-09-06 Basf Ag Chinolin-4-carbonsaeurederivate und deren verwendung
US4992448A (en) * 1989-10-24 1991-02-12 Hoechst-Roussel Pharmaceuticals Inc. Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders
US5037835A (en) * 1989-10-24 1991-08-06 Hoechst-Roussel Pharmaceuticals Inc. Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders
EP0449565B1 (de) * 1990-03-26 1997-05-14 Matsushita Electric Industrial Co., Ltd. Lichtempfindliches Material für Elektrophotographie
US5482967A (en) * 1992-09-04 1996-01-09 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
KR100316571B1 (ko) * 1994-05-27 2002-05-30 파올로 비지, 엔리꼬 카쭐라니 타키키닌nk3수용체길항제로서퀴놀린유도체
US5607936A (en) * 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists

Also Published As

Publication number Publication date
NO326714B1 (no) 2009-02-02
CN1156451A (zh) 1997-08-06
US20060160846A1 (en) 2006-07-20
SK4799A3 (en) 1999-06-11
SK151496A3 (en) 1997-07-09
CZ347096A3 (en) 1997-10-15
ATE273959T1 (de) 2004-09-15
IL113844A (en) 2005-05-17
PL317381A1 (en) 1997-04-01
JP3664492B2 (ja) 2005-06-29
DK0804419T3 (da) 2003-11-24
FI990268A (fi) 1999-02-10
MY129596A (en) 2007-04-30
CA2191352C (en) 2001-01-30
EP0804419B1 (de) 2003-08-06
PT804419E (pt) 2003-12-31
TW533199B (en) 2003-05-21
PL186075B1 (pl) 2003-10-31
PT940391E (pt) 2004-12-31
NO965036D0 (no) 1996-11-26
OA10592A (en) 2002-08-27
JP2007126475A (ja) 2007-05-24
SK282722B6 (sk) 2002-11-06
NO991813L (no) 1997-01-24
FI119721B (fi) 2009-02-27
US7482458B2 (en) 2009-01-27
NZ287442A (en) 1998-05-27
JP2000026314A (ja) 2000-01-25
CN1092642C (zh) 2002-10-16
CA2191352A1 (en) 1995-12-07
AR037069A2 (es) 2004-10-20
HUT76286A (en) 1997-07-28
JPH10500697A (ja) 1998-01-20
HK1003884A1 (en) 1998-11-13
EP0940391A3 (de) 1999-11-10
KR100316571B1 (ko) 2002-05-30
AP9500745A0 (en) 1995-07-31
FI115052B (fi) 2005-02-28
US20050096316A1 (en) 2005-05-05
DE69531458T2 (de) 2004-08-05
FI964712A0 (fi) 1996-11-26
ES2227769T3 (es) 2005-04-01
PL186665B1 (pl) 2004-02-27
UA51623C2 (uk) 2002-12-16
HK1024469A1 (en) 2000-10-13
ES2204952T3 (es) 2004-05-01
ATE246677T1 (de) 2003-08-15
DE69531458D1 (de) 2003-09-11
NO307783B1 (no) 2000-05-29
CN1428145A (zh) 2003-07-09
CN1276211A (zh) 2000-12-13
NO965036L (no) 1997-01-24
FI964712A (fi) 1997-01-23
BG101008A (en) 1997-08-29
US5811553A (en) 1998-09-22
AU699319B2 (en) 1998-12-03
BG64004B1 (bg) 2003-09-30
MA23560A1 (fr) 1995-12-31
NO991813D0 (no) 1999-04-16
JP2002179594A (ja) 2002-06-26
IL113844A0 (en) 1995-08-31
WO1995032948A1 (en) 1995-12-07
EP0940391B1 (de) 2004-08-18
HU9603262D0 (en) 1997-01-28
DE69533408T2 (de) 2005-09-08
SA95160290A (ar) 2005-12-03
BR9507788A (pt) 1997-09-23
CZ291476B6 (cs) 2003-03-12
JP2005068155A (ja) 2005-03-17
TW427977B (en) 2001-04-01
EP0804419A1 (de) 1997-11-05
DZ1889A1 (fr) 2002-02-17
RO114445B1 (ro) 1999-04-30
AU2616495A (en) 1995-12-21
MX9605903A (es) 1998-08-30
EP0940391A2 (de) 1999-09-08
AP578A (en) 1997-03-26
US20030236281A1 (en) 2003-12-25
FI990268A0 (fi) 1999-02-10
SK282721B6 (sk) 2002-11-06
US6608083B1 (en) 2003-08-19
HU226535B1 (en) 2009-03-30
BG103181A (bg) 1999-09-30
SA95160290B1 (ar) 2006-06-21

Similar Documents

Publication Publication Date Title
DE69533408D1 (de) Chinolinderivate als Tachykinin NK3 Rezeptor Antagonisten
DE69728392D1 (de) Indolderivate verwendbar als endothelinrezeptorantagonisten
NO951613D0 (no) Ikke-peptidyl tachykinin reseptorantagonister
CY2505B1 (en) Quinoline derivatives as nk3 antagonists
DE69531331D1 (de) Phenylpiperidinderivate als neurokinin antagonists
DE69734833D1 (de) Vitronektin rezeptor antagonisten
ATE187172T1 (de) Chinolin-2-on derivate als serotonin antagonisten
DE69714265D1 (de) Tetrahydrochinolinderivate als eaa antagonisten
DE69626220D1 (de) 3-azetidinylalkylpiperidine oder -pyrrolidine als tachykinin antagonisten
ATE286022T1 (de) Naphthalin-carboxamide als tachykinin rezeptorantagonisten
ATE233243T1 (de) Salze von chinolinderivaten als nk3 antagonisten
DE69703242T2 (de) Indolin-derivate verwendbar als 5-ht-2c rezeptor-antagonisten
ID24468A (id) 2-asilaminopropanamina sebagai antagonis reseptor tachykinin
DE69735811D1 (de) Piperazinoderivate als neurokinin-antagonisten
DE69717449T2 (de) Indolin-derivate verwendbar als 5-ht-2c rezeptor-antagonisten
ATE206421T1 (de) Heterocyclisch substituierte piperazonderivate als tachykinin rezeptor antagonisten
DE69617010D1 (de) Isazole derivate als fibrinogen-rezeptor-antagonisten
ID24309A (id) 2-asilaminopropanamina sebagai antagonis reseptor tachykinin
DK0940391T3 (da) Quinolinderivater som tachykinin-NK3-receptor-antagonister
DE69714019D1 (de) 1,4-dihydropyridin-verbindungen als bradykinin-antagonisten
SI0940391T1 (en) Quinoline derivatives as tachykinin NK3 receptor antagonists

Legal Events

Date Code Title Description
8364 No opposition during term of opposition